Key result
Increasing duration of prasugrel pre-treatment did not improve the composite of cardiovascular death, MI, stroke, urgent revascularization, or bailout use.
Why the study?
In the ACCOAST trial, prasugrel pretreatment vs placebo caused excess bleeding without ischemic benefit in non-ST-segment elevation MI, but whether patients with the longest pretreatment duration had an ischemic benefit was unknown.
Does the duration of prasugrel pre-treatment before angiography affect ischemic or bleeding outcomes in patients with NSTEMI?
RCT (n=4,001)
randomized
Does the duration of prasugrel pre-treatment before angiography affect ischemic or bleeding outcomes in patients with NSTEMI?
Answers are grounded in this paper and cite their sources.
The lack of ischemic benefit and excess bleeding risk associated with prasugrel pre-treatment in NSTEMI patients remains consistent regardless of the time interval to coronary angiography.
BACKGROUND: In the ACCOAST (A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction) trial, the prasugrel pre-treatment strategy versus placebo was associated with excess bleeding complications and no improved ischemic outcome in non-ST-segment elevation myocardial infarction (MI). Whether patients with the longest pre-treatment duration had an ischemic benefit is unknown. OBJECTIVES: This pre-specified analysis of the ACCOAST trial aimed to assess the effect of pre-treatment duration with prasugrel (time from randomization to angiography) on outcomes. METHODS: Within the 4,033 patients randomized in the ACCOAST trial, pre-treatment duration was available in 4,001 patients (99.2%). The population of the trial was divided into quartiles of pre-treatment duration (0.1 to 2.5 h, 2.5 to 3.9 h, 3.9 to 13.6 h, and >13.6 h) with an evaluation of the primary efficacy endpoint of cardiovascular death, MI, stroke, urgent revascularization or glycoprotein IIb/IIIa inhibitor bailout use. Secondary efficacy outcomes including cardiovascular death, MI, or stroke; all-cause death; stent thrombosis and safety outcomes (all coronary artery bypass graft [CABG] or non-CABG TIMI [Thrombolysis In Myocardial Infarction] major bleeding) were also evaluated at 7 days. RESULTS: The primary efficacy outcome of cardiovascular death, MI, stroke, urgent revascularization or glycoprotein IIb/IIIa inhibitor bailout use did not differ between the quartiles of pre-treatment duration in the trial population (p = 0.17 for interaction). None of the secondary efficacy outcomes were found to be dependent on pre-treatment duration. The safety outcome of all CABG or non-CABG TIMI major bleeding did not differ between the quartiles of pre-treatment duration (p = 0.37 for interaction). CONCLUSIONS: In non-ST-segment elevation MI patients, the excess risk of bleeding and the absence of ischemic benefit were consistent across the quartiles of increasing duration of prasugrel pre-treatment. (A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction [ACCOAST]; NCT01015287).
No takes yet. Share an insight, caveat, or question.
Silvain et al. (2019) conducted an RCT in Non-ST-segment elevation myocardial infarction (n=4,001). Prasugrel pre-treatment vs. Different quartiles of pre-treatment duration (0.1-2.5 h, 2.5-3.9 h, 3.9-13.6 h, >13.6 h) was evaluated on Cardiovascular death, MI, stroke, urgent revascularization or glycoprotein IIb/IIIa inhibitor bailout use (p=0.17 for interaction). Increasing duration of prasugrel pre-treatment did not improve the composite of cardiovascular death, MI, stroke, urgent revascularization, or bailout use.
Synapse has enriched 10 related papers. Consider them for comparative context: